drugset / Trial / NCT03641755
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Phase 1
Active not recruiting
10 enrolled
Dana-Farber Cancer Institute
AstraZeneca · collabCyclacel Pharmaceuticals, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: * Sapacitabine (CYC682) * Olaparib (Lynparza™)
Timeline
- Start
- 2018-10-01
- Primary completion
- 2022-04-27
- Completion
- 2026-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | sapacitabine | Small molecule | 100 mg | Oral |
| Subject | sapacitabine | Small molecule | 150 mg | Oral |
| Subject | sapacitabine | Small molecule | 200 mg | Oral |
| Subject | sapacitabine | Small molecule | 250 mg | Oral |